Ignite Creation Date:
2025-12-24 @ 9:11 PM
Ignite Modification Date:
2026-06-28 @ 7:59 PM
Study NCT ID:
NCT04230304
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-03
First Post:
2020-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study
Sponsor:
Mayo Clinic
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Chronic Lymphocytic Leukemia | View |
| None | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | View |
| None | Recurrent Small Lymphocytic Lymphoma | View |
| None | Refractory Chronic Lymphocytic Leukemia | View |
| None | Refractory Small Lymphocytic Lymphoma | View |
Keywords: